Home Health & Wellness New Study Sheds Light on Immune Differences in Sarcoidosis and TB, Boosting Diagnosis and Treatment

New Study Sheds Light on Immune Differences in Sarcoidosis and TB, Boosting Diagnosis and Treatment

Reading Time: 2 minutes

Sarcoidosis is characterised by the formation of granulomas (clusters of immune cells) in various organs, primarily the lungs. Unlike tuberculosis (TB), which is caused by the Mycobacterium tuberculosis bacterium, sarcoidosis does not have a known infectious trigger. This makes it a particularly complex disease to study, as its aetiology might involve genetic, environmental, and immunological factors.

Recent studies using advanced technologies like single-cell RNA sequencing and spatial transcriptomics have provided unprecedented insights into the cellular and molecular makeup of granulomas. In sarcoidosis, granulomas are rich in CD4+ T cells that produce a high level of interferon-gamma (IFN-γ), a key cytokine in immune system signaling. These findings suggest that, despite the lack of a pathogen, the immune system in sarcoidosis patients is highly active and potentially self-perpetuating. The study is published in the Journal of Clinical Investigation.

In contrast, the granulomas of TB patients show a different pattern. They are heavily influenced by the presence of Mycobacterium tuberculosis, which actively manipulates immune responses. TB granulomas typically feature a mix of immune-suppressing cells like regulatory T cells (Tregs) and PD-L1+ myeloid cells, which help the bacteria evade the host’s immune system. This adaptation allows the bacteria to survive within the host, making TB a challenging disease to eradicate.

One of the pivotal studies highlighted in this review compares the granuloma environments in sarcoidosis and TB. Researchers found that while TB granulomas create an immunosuppressive environment facilitated by the bacterium’s secretions, sarcoidosis granulomas do not show these immunosuppressive markers. Instead, sarcoidosis features an aggressive immune response, suggesting different underlying mechanisms driving granuloma maintenance and progression in these diseases.

The role of genetic factors in sarcoidosis is also a significant area of research. Variants in several immune-related genes, such as those involved in the major histocompatibility complex (MHC) and tumour necrosis factor (TNF) pathways, have been linked to sarcoidosis susceptibility and disease course. These genetic insights are crucial for understanding why some patients develop severe forms of the disease and may lead to targeted therapies that can mitigate these risks.

Another emerging area of interest is the potential use of biomarkers to differentiate between sarcoidosis and TB. This is particularly challenging in regions where TB is prevalent, as the clinical features of both diseases can overlap significantly. Biomarkers specific to the type of granuloma and immune responses could lead to more accurate diagnoses and personalised treatment plans.

Future research directions include further delineation of the pathways involved in granuloma formation and maintenance, particularly through longitudinal studies and larger patient cohorts. Additionally, exploring the potential for therapeutic interventions that target specific pathways, such as mTOR signaling in sarcoidosis or PD-L1 in TB, may offer new treatment paradigms.

© Copyright 2014–2034 Psychreg Ltd